InterCure Ltd.: Business Overview, Financials & Competitive Analysis
InterCure Ltd. scores 7/10 on the AskCyborg Cyborg Score (Strong). Profitable leader in underserved non-North American cannabis market with vertically integrated model, proven execution, and disciplined international expansion. The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA and demonstrated disciplined execution despite operational disruptions from the October 2023 conflict. Strong revenue growth and successful market expansion in Germany.
What is InterCure Ltd.'s industry? InterCure Ltd. (intercure.co) operates in Pharmaceutical-Grade Cannabis Production & Distribution. AskCyborg classifies InterCure Ltd. under Pharmaceutical-Grade Cannabis Production & Distribution in its company registry.
InterCure Ltd. (dba Canndoc) is the leading, profitable, and fastest-growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer a...
Cyborg Score thesis
Profitable leader in underserved non-North American cannabis market with vertically integrated model, proven execution, and...
Read the full analyst-debate transcript →Get the Latest InterCure Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeInterCure Ltd. Overview
Pro stress-test →InterCure Ltd. (dba Canndoc) is the leading, profitable, and fastest-growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. The company is executing a significant international expansion strategy while maintaining profitability across multiple markets.
Strategic Profile
Pro stress-test →InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated 'seed-to-sale' model to lead the fastest growing cannabis global market outside of North America. During the second half of 2025, the Company generated its first significant revenues from the German market. The company has achieved twelve consecutive half-years of positive Adjusted EBITDA and is pursuing strategic acquisitions and partnerships to strengthen its global position.
Competitive Landscape
Pro stress-test →InterCure competes in the international cannabis market against established North American producers and emerging European players. The company maintains competitive advantages through its GMP-certified pharmaceutical-grade products, vertically integrated operations, and partnerships with global cannabis brands like Cookies™ and Binske. Primary competition includes North American legacy producers seeking international expansion, while InterCure's dominant position in Israel's regulated medical cannabis market provides a strategic advantage.
Industry Context
InterCure Ltd. operates in Pharmaceutical-Grade Cannabis Production & Distribution.
Key facts
Founded: 2018 · Headquarters: Herzliya, Israel · Revenue: NIS 265 million (2025E)